Compare NKSH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | ALXO |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 205.9M |
| IPO Year | 1995 | 2020 |
| Metric | NKSH | ALXO |
|---|---|---|
| Price | $36.57 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 29.0K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | 26.36 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.62 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $27.00 | $0.44 |
| 52 Week High | $40.00 | $2.66 |
| Indicator | NKSH | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 56.12 |
| Support Level | $34.87 | $1.99 |
| Resistance Level | $38.08 | $2.31 |
| Average True Range (ATR) | 1.18 | 0.19 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 58.37 | 40.20 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.